Active Ingredient History
Bisoprolol is a cardioselective beta1-adrenergic blocking agent. It lower the heart rate and blood pressure and may be used to reduce workload on the heart and hence oxygen demands. This results in a reduction of heart rate, cardiac output, systolic and diastolic blood pressure, and possibly reflex orthostatic hypotension. Bisoprolol can be used to treat cardiovascular diseases such as hypertension, coronary heart disease, arrhythmias, ischemic heart diseases, and myocardial infarction after the acute event. General side effects are: fatigue, asthenia, chest pain, malaise, edema, weight gain, angioedema. Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate, shortening its elimination half-life. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Coronary Syndrome (Phase 2)
Angina Pectoris (Phase 4)
Angina Pectoris, Variant (Phase 4)
Angina, Stable (Phase 4)
Aortic Aneurysm, Abdominal (Early Phase 1)
Aortic Valve Stenosis (Phase 4)
Atrial Fibrillation (Phase 4)
Atrial Function, Left (Phase 3)
Blood Loss, Surgical (Early Phase 1)
Blood Pressure (Phase 4)
Breast Neoplasms (Phase 3)
Cardiomyopathies (Phase 4)
Cardiomyopathy, Dilated (Phase 2/Phase 3)
Cardiotoxicity (Phase 3)
Cardiovascular Diseases (Phase 4)
Chagas Cardiomyopathy (Phase 3)
Coronary Artery Bypass (Phase 4)
Coronary Artery Disease (Phase 4)
Coronary Disease (Phase 4)
Coronary Vasospasm (Phase 4)
Diabetes Mellitus (Phase 2/Phase 3)
Diabetes Mellitus, Type 2 (Phase 4)
Essential Hypertension (Phase 4)
Familial Primary Pulmonary Hypertension (Phase 1/Phase 2)
Fasting (Phase 1)
General Surgery (Early Phase 1)
Healthy Volunteers (Phase 1)
Heart Diseases (Phase 4)
Heart Failure (Phase 4)
Heart Failure, Diastolic (Phase 3)
Heart Failure, Systolic (Phase 4)
Heart Rate (Early Phase 1)
Hypertension (Phase 4)
Hypertension, Renal (Phase 4)
Insulin Resistance (Phase 4)
Metabolic Syndrome (Phase 4)
Microvascular Angina (Phase 4)
Muscular Dystrophy, Duchenne (Phase 2/Phase 3)
Myocardial Infarction (Phase 4)
Non-ST Elevated Myocardial Infarction (Phase 4)
Pharmacogenetics (Phase 4)
Pharmacokinetics (Phase 1)
Pheochromocytoma (Phase 2)
Postoperative Complications (Phase 4)
Pulmonary Disease, Chronic Obstructive (Phase 4)
ST Elevation Myocardial Infarction (Phase 4)
Systole (Phase 3)
Ventricular Dysfunction, Left (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
